Ye XS, Yu C, Aggarwal A, et al. Genomic alterations and molecular subtypes of gastric cancers in asians. Chin J Cancer. 2016;35:42.
Article
PubMed
PubMed Central
Google Scholar
Cavalli FMG, Remke M, Rampasek L, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer cell. 2017;31(6):737–54.
Article
CAS
PubMed
Google Scholar
Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.
Article
PubMed
PubMed Central
Google Scholar
Schwarz RF, Ng CK, Cooke SL, et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med. 2015;12(2):e1001789.
Article
PubMed
PubMed Central
Google Scholar
Izumchenko E, Chang X, Brait M, et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat Commun. 2015;6:8258.
Article
PubMed
PubMed Central
Google Scholar
Ross-Innes CS, Becq J, Warren A, et al. Whole-genome sequencing provides new insights into the clonal architecture of barrett’s esophagus and esophageal adenocarcinoma. Nat Genet. 2015;47(9):1038–46.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim KT, Lee HW, Lee HO, et al. Single-cell mrna sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells. Genome Biol. 2015;16:127.
Article
PubMed
PubMed Central
Google Scholar
Kim H, Zheng S, Amini SS, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015;25(3):316–27.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–8.
Article
CAS
PubMed
Google Scholar
Morrissy AS, Cavalli FMG, Remke M, et al. Spatial heterogeneity in medulloblastoma. Nat Genet. 2017;49(5):780–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Moss TJ, Qi Y, Xi L, et al. Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur Urol. 2017;72:641–9.
Article
CAS
PubMed
Google Scholar
Sun C, Fang Y, Yin J, et al. Rational combination therapy with parp and mek inhibitors capitalizes on therapeutic liabilities in ras mutant cancers. Sci Transl Med. 2017;9:392.
Article
Google Scholar
Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (shiva): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–34.
Article
PubMed
Google Scholar
Stockley TL, Oza AM, Berman HK, et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the princess margaret impact/compact trial. Genome Med. 2016;8(1):109.
Article
PubMed
PubMed Central
Google Scholar
Tannock IF, Hickman JA. Limits to personalized cancer medicine. N Engl J Med. 2016;375(13):1289–94.
Article
PubMed
Google Scholar
Yu C, Yu J, Yao X, et al. Discovery of biclonal origin and a novel oncogene slc12a5 in colon cancer by single-cell sequencing. Cell Res. 2014;24(6):701–12.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ling S, Hu Z, Yang Z, et al. Extremely high genetic diversity in a single tumor points to prevalence of non-darwinian cell evolution. Proc Natl Acad Sci USA. 2015;47:6496–505.
Article
Google Scholar
Yang Z, Li C, Fan Z, et al. Single-cell sequencing reveals variants in ARID1A, GPRC5A and MLL2 driving self-renewal of human bladder cancer stem cells. Eur Urol. 2017;71(1):8–12.
Article
PubMed
Google Scholar
Li C, Wu S, Yang Z, et al. Single-cell exome sequencing identifies mutations in kcp, loc440040, and loc440563 as drivers in renal cell carcinoma stem cells. Cell Res. 2017;27(4):590–3.
Article
CAS
PubMed
Google Scholar
Liu S, Cong Y, Wang D, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2014;2(1):78–91.
Article
CAS
Google Scholar
Gupta PB, Fillmore CM, Jiang G, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011;146(4):633–44.
Article
CAS
PubMed
Google Scholar
Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in brca1 mutation carriers. Nat Med. 2009;15(8):907–13.
Article
CAS
PubMed
Google Scholar
Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.
Article
CAS
PubMed
PubMed Central
Google Scholar
Van Keymeulen A, Lee MY, Ousset M, et al. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature. 2015;525(7567):119–23.
Article
PubMed
Google Scholar
Koren S, Reavie L, Couto JP, et al. PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature. 2015;525(7567):114–8.
Article
CAS
PubMed
Google Scholar
McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–28.
Article
CAS
PubMed
Google Scholar
Al-Hussaini H, Subramanyam D, Reedijk M, et al. Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther. 2011;10(1):9–15.
Article
CAS
PubMed
Google Scholar
King TD, Suto MJ, Li Y. The wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem. 2012;113(1):13–8.
Article
CAS
PubMed
Google Scholar
Korkaya H, Paulson A, Iovino F, et al. Her2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008;27(47):6120–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving nf-kappab, lin28, let-7 microrna, and il6 links inflammation to cell transformation. Cell. 2009;139(4):693–706.
Article
CAS
PubMed
PubMed Central
Google Scholar
Voss MH, Hakimi AA, Pham CG, et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res. 2014;20(7):1955–64.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zardavas D, Irrthum A, Swanton C, et al. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 2015;12(7):381–94.
Article
CAS
PubMed
Google Scholar
Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–9.
Article
CAS
PubMed
Google Scholar
Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Meric-Bernstam F, Brusco L, Shaw K, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol. 2015;33(25):2753–62.
Article
PubMed
PubMed Central
Google Scholar
Bhola NE, Balko JM, Dugger TC, et al. Tgf-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013;123(3):1348–58.
Article
CAS
PubMed
PubMed Central
Google Scholar
Eser S, Reiff N, Messer M, et al. Selective requirement of PI3K/PDK1 signaling for kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell. 2013;23(3):406–20.
Article
CAS
PubMed
Google Scholar
Tovy A, Spiro A, McCarthy R, et al. P53 is essential for DNA methylation homeostasis in naive embryonic stem cells, and its loss promotes clonal heterogeneity. Genes Dev. 2017;10:959–72.
Article
Google Scholar
Hata AN, Niederst MJ, Archibald HL, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22(3):262–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Oxnard GR. The cellular origins of drug resistance in cancer. Nat Med. 2016;22(3):232–4.
Article
CAS
PubMed
Google Scholar
Shaffer SM, Dunagin MC, Torborg SR, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017;546(7658):431–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27(1):15–26.
Article
CAS
PubMed
Google Scholar
Sanchez-Laorden B, Viros A, Girotti MR, et al. BRAF inhibitors induce metastasis in ras mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal. 2014;7(318):ra30.
Article
PubMed
Google Scholar
Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91–101.
Article
CAS
PubMed
PubMed Central
Google Scholar
Duncan JS, Whittle MC, Nakamura K, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 2012;149(2):307–21.
Article
CAS
PubMed
PubMed Central
Google Scholar
Klempner SJ, Myers AP, Cantley LC. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov. 2013;3(12):1345–54.
Article
CAS
PubMed
Google Scholar
Shimizu T, Tolcher AW, Papadopoulos KP, et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res. 2012;18(8):2316–25.
Article
CAS
PubMed
Google Scholar
Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to mek inhibition. Cancer Res. 2009;69(2):565–72.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hoeflich KP, O’Brien C, Boyd Z, et al. In vivo antitumor activity of mek and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res. 2009;15(14):4649–64.
Article
CAS
PubMed
Google Scholar
Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14(12):1351–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80–93.
Article
CAS
PubMed
Google Scholar
Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.
Article
PubMed
Google Scholar
Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF v600 mutations. N Engl J Med. 2012;367(18):1694–703.
Article
CAS
PubMed
PubMed Central
Google Scholar
Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54(5):716–27.
Article
CAS
PubMed
PubMed Central
Google Scholar
Easwaran H, Johnstone SE, Van Neste L, et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res. 2012;22(5):837–49.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125(2):315–26.
Article
CAS
PubMed
Google Scholar
Azuara V, Perry P, Sauer S, et al. Chromatin signatures of pluripotent cell lines. Nat Cell Biol. 2006;8(5):532–8.
Article
CAS
PubMed
Google Scholar
Azad N, Zahnow CA, Rudin CM, et al. The future of epigenetic therapy in solid tumours–lessons from the past. Nat Rev Clin Oncol. 2013;10(5):256–66.
Article
CAS
PubMed
PubMed Central
Google Scholar
Baylin SB, Jones PA. A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer. 2011;11(10):726–34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14(3):275–91.
Article
CAS
PubMed
Google Scholar
Jensen PB, Holm B, Sorensen M, et al. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer. 1997;75(6):869–77.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hill BT. Potential of continuous tumour cell lines for establishing patterns of cross-resistance and collateral sensitivity in vitro. Drugs Exp Clin Res. 1986;12(1–3):293–8.
CAS
PubMed
Google Scholar
Zhao B, Sedlak JC, Srinivas R, et al. Exploiting temporal collateral sensitivity in tumor clonal evolution. Cell. 2016;165(1):234–46.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cancer Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25.
Article
Google Scholar
Varghese AM, Berger MF. Advancing clinical oncology through genome biology and technology. Genome Biol. 2014;15(8):427.
Article
PubMed
PubMed Central
Google Scholar
Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–9.
Article
Google Scholar
Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22.
Article
Google Scholar
Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Eng J Med. 2013;368(22):2059–74.
Article
Google Scholar
Cancer Genome Atlas Research N, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.
Article
Google Scholar
Jamal-Hanjani M, Hackshaw A, Ngai Y, et al. Tracking genomic cancer evolution for precision medicine: the lung tracerx study. PLoS Biol. 2014;12(7):e1001906.
Article
PubMed
PubMed Central
Google Scholar
Jamal-Hanjani M, Wilson GA, Horswell S, et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol. 2016;27(5):862–7.
Article
CAS
PubMed
Google Scholar
Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376(22):2109–21.
Article
CAS
PubMed
Google Scholar
Werner HM, Mills GB, Ram PT. Cancer systems biology: a peek into the future of patient care? Nat Rev Clin Oncol. 2014;11(3):167–76.
Article
PubMed
PubMed Central
Google Scholar
Du W, Elemento O. Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene. 2015;34(25):3215–25.
Article
CAS
PubMed
Google Scholar
Iorio F, Knijnenburg TA, Vis DJ, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166(3):740–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med. 2015;21(5):440–8.
Article
CAS
PubMed
Google Scholar
Enriquez-Navas PM, Kam Y, Das T, et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Transl Med. 2016;8(327):327ra324.
Article
Google Scholar
McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit t cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Misale S, Bozic I, Tong J, et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nat Commun. 2015;6:8305.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198f. N Engl J Med. 2016;374(1):54–61.
Article
CAS
PubMed
Google Scholar
Amirouchene-Angelozzi N, Swanton C, Bardelli A. Tumor evolution as a therapeutic target. Cancer Discov. 2017;7:805–17.
Article
Google Scholar
Qin Z, Ljubimov VA, Zhou C, et al. Cell-free circulating tumor DNA in cancer. Chin J Cancer. 2016;35:36.
Article
PubMed
PubMed Central
Google Scholar
Siravegna G, Bardelli A. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol. 2014;15(8):449.
Article
PubMed
PubMed Central
Google Scholar
Mateo J, Gerlinger M, Rodrigues DN, et al. The promise of circulating tumor cell analysis in cancer management. Genome Biol. 2014;15(8):448.
Article
PubMed
PubMed Central
Google Scholar
Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506–10.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen G, Mulla WA, Kucharavy A, et al. Targeting the adaptability of heterogeneous aneuploids. Cell. 2015;160(4):771–84.
Article
CAS
PubMed
PubMed Central
Google Scholar